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To the Editor 
Physicians can treat psoriasis patients with several effective treatments, however the 
response is individual and even the most effective therapies do sometimes not lead to a 
success of treatment. Currently, possible genetic markers that can predict individual therapy 
response are investigated.  
Up to now 45 genes have been identified to be associated with psoriasis [1]. Of all genes, 
HLA-C*06, or also known as HLA-Cw6 or PSORS1 displays the strongest association [2]. This 
allotype is not only a risk factor for psoriasis, but has also been found of use in predicting 
therapy responses. Previous studies had shown a higher response rate of HLA-Cw6+ patients 
for TNF-alpha [3], methotrexate [4] and especially ustekinumab [5-7]. Li et al. analysed 523 
patients [5]. HLA-Cw6+ patients tended to have a higher response rate to ustekinumab. This 
difference was however only modest and potentially of limited clinical utility. Most clinical 
centers including tertiary referral centers do not tend to accumulate hundreds of moderate-
to-severe psoriasis patients treated with a single drug. Therefore, it is of interest to 
investigate whether the screening of HLA-Cw6 is of clinical utility in a day-to-day clinic. If so, 
we hypothesized, prescreening could possibly enhance patient care and aid clinical 
treatment decisions. 
 
The patients presented to our clinic between 1 January 2010 and 31 March 2017 were 
included after signing an informed consent. We retrospectively collected HLA-genotyping 
data from patients. Genomic DNA was isolated from ethylenediamine tetraacetic acid 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
(EDTA) tubes with venous blood. The samples were genotyped using a primer-specific 
polymerase chain reaction (Olerup HLA-C*06-SSP® product number 101.614-12u, Vienna, 
Austria). 
Secukinumab was administered in the standard doses and treatment responses were 
measured at 3 months by PASI. 
18 patients (7 women, 11 men) were included in this retrospective study. On average, the 
patients were 46.4 ± 9.5 (21-61) years old and the PASI at baseline was 8.2 points. 10 
patients were positive for the HLA-Cw6 allele, 8 were negative. 
The majority of patients in both groups reached PASI 50 (Table 1), but not PASI 75 or PASI 
90. The average PASI improvement was 74.2% (Cw6+) vs. 62.4% (Cw6-), showing no 
significant difference (p= 0.397) between these two groups (Figure 1).  
On average, our patients had a lower PASI baseline than in comparable studies. In 
randomized, clinical trials patients tend to have a higher PASI since patients need to be 
treatment naïve or have not performed treatment for a certain amount of time. Our real life 
data includes patients that had previously been treated - even with other biologics - 
explaining this lower baseline PASI.  
Even though we did not find significant differences in our small cohort, a larger trial might 
indeed show a statistical difference. Using the published data for predicting success of 
ustekinumab at 16 weeks with HLA-Cw6 [5], a power analysis (α = 0.05, power= 90%) shows 
that overall 216 patients would be needed to confirm such a difference. As most centers 
treat their patients with a variety of anti-psoriasis drugs, the average amount of patients 
under secukinumab per clinic will be usually way below this number. In addition, other than 
for purposes of treatment response prediction, routine HLA-Cw6 testing might not be 
justified from a health economy perspective. We believe that for a tertiary hospital with less 
than 20 patients treated with secukinumab, this statistical difference is not actionable and 
of relevance to patients. Therefore, even though larger studies could in the future 
demonstrate a statistical tendency for differential treatment responses for secukinumab in 
certain HLA allotypes, HLA-Cw6 testing might not be warranted at this time. 
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Tables and Figure legends 
Table 1. 
Patients’ characteristiscs, PASI at baseline and treatment response. 
 
Figure 1. 
Treatment response after 12 weeks. 
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Table 1. 
Patients’ characteristiscs, PASI at baseline and treatment response. 
 
 all Cw6+ 
 
Cw6- 
Patients (n) 
 
18 10 8 
Age 46.4 ± 9.5 (21-61) 46 ± 6.67 (21-61) 47 ± 12.86 (33-53) 
Sex    
Male 12 7 5 
Female 8 3 5 
    
PASI at baseline 8.2 ± 6.3 (0-26.7) 8.65 ± 4.9 (0-17.8) 7.73 ± 8.4 (0-26.7) 
PASI ≤5 5 2 3 
PASI 5-10 7 3 4 
PASI ≥ 10 6 5 1 
    
Treatment response    
PASI 50 11 6 (10) 5 (8) 
PASI 75 10 5 (10) 5 (8) 
PASI 90 5 3 (10) 2 (8) 
Average PASI improvement 64.96 ± 36.83 74.2% ± 36.1 62.4% ± 39.8 
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